NICE impact report: lung cancer

NICE impact reports review how NICE recommendations for evidence-based and cost-effective care are being used in priority areas of the health and care system, helping to improve outcomes where this is needed most. This report considers how NICE’s evidence based guidance can contribute to improvements in the care of people with lung cancer.

Image source:

Lung cancer is the third most common cancer in England and is the leading cause of  cancer death. In 2017, there were almost 39,000 new cases of lung cancer and just over 28,000 related deaths.

Since 2005 and the publication of NICE’s first guideline on lung cancer, NICE has produced a suite of lung cancer related guidance, which aim to improve outcomes by focusing on survival rates and ensuring the most effective tests and treatments are used.

In England, overall survival rates for cancers are improving but there is still a marked difference between lung cancer and other cancers. Between 2012 and 2016 more than 95% of people with breast or prostate cancer survived more than 1 year after their diagnosis, compared to less than 40% of people with lung cancer.

There is an even greater difference between 5-year survival rates. More than 85% of people with breast or prostate cancer survived more than 5 years but just over 15% of people with lung cancer survived this long. When comparing with other countries in Europe, England’s long-term survival for people with lung cancer is poor, ranking 26th out of 29 countries.

Further detail at NICE

Full report: NICEimpact Lung Cancer

[NICE Guideline] Thyroid disease: assessment and management

NICE |November 2019 | Thyroid disease: assessment and management |NICE guideline [NG145] 

NICE has published Thyroid disease: assessment and managementThis guideline covers investigating all suspected thyroid disease and managing primary thyroid disease (related to the thyroid rather than the pituitary gland). It does not cover managing thyroid cancer or thyroid disease in pregnancy. It aims to improve quality of life by making recommendations on diagnosis, treatment, long-term care and support.

Further information from NICE 

[NICE Guideline] Fever in under 5s: assessment and initial management

NICE |  November  2019 | Fever in under 5s: assessment and initial management

This guideline covers the assessment and early management of fever with no obvious cause in children aged under 5. It aims to improve clinical assessment and help healthcare professionals diagnose serious illness among young children who present with fever in primary and secondary care.

Full details from NICE

NICE updates antidepressant guidelines to reflect severity and length of withdrawal symptoms

BMJ | 2019| NICE updates antidepressant guidelines to reflect severity and length of withdrawal symptoms| 367| BMJ | doi: (Published 18 October 2019)

The National Institute for Health and Care Excellence (NICE) has amended its guidelines on depression to recognise the severity and length of antidepressant withdrawal symptoms.

The guidance on treating depression in adults now states that withdrawal symptoms may be severe and protracted in some patients.

NICE’s previous guideline, which was originally published in 2009 and updated last year, said that withdrawal symptoms are “usually mild and self limiting over about one week.”

But in an amendment, NICE acknowledges that “there is substantial variation in people’s experience, with symptoms lasting much longer (sometimes months or more) and being more severe for some patients.”

Clinicians should “advise people taking antidepressant medication that, before stopping it, they should discuss this with their practitioner,” the updated guideline says.

Read the full article from The BMJ